H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on AC Immune SA (ACIU – Research Report) today and set a price target of $16.00. The company's shares closed last Thursday at $3.42, close to its 52-week low of $3.34. According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -13.7% and a 28.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. AC Immune SA has an analyst consensus of Moderate Buy, with a price target consensus of $16.00.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-ac-immune-sas-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more AC Immune Charts.
AC Immune (NASDAQ:ACIU)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more AC Immune Charts.